Search

Alkylation of benzene with ethylene to ethylbenzene over a β-zeolite catalyst is carried out in the five different near critical regions. With the application of X-ray diffraction (XRD) and scanning electron microscope (SEM), structures of the catalysts used under the five different near critical conditions are compared with those of the fresh catalyst. The results show that the high pressure operating conditions, including the supercritical fluid operation, may be harmful to the catalyst structure, and the operation in the vapor–liquid state near the critical point may cause heavy destruction to the catalyst. The coking mechanism of the catalysts is suggested based on element material analysis (EMA) and electron paramagnetic resonance (EPR) characterization. Supercritical and other near critical operations are compared. [Copyright &y& Elsevier]

Malignant giant cell tumor of bone (MGCTB) is extremely rare. Currently, population-based prognosis studies are lacking. This study aimed to determine the impact of demographics, tumor characteristics, and treatment on prognosis among patients with MGCTB. The Surveillance, Epidemiology, and End Results database was used to identify patients with MGCTB from 1984 to 2013. Kaplan-Meier analyses were performed to determine the overall survival (OS). Univariable and multivariable Cox analyses were conducted to identify prognostic factors. There were 250 patients with MGCTB included in our study. The multivariate Cox analysis revealed that age at diagnosis (hazard ratio [HR]: 1.09; 95% confidence interval [CI]: 1.07–1.11; P < 0.001), tumor size (HR: 7.04; 95% CI: 2.38–20.77; P < 0.001), tumor extension (regional vs. localized, HR: 2.64; 95% CI: 1.10–6.34; P = 0.030; distant vs. localized, HR: 6.12; 95% CI: 2.27–16.49; P < 0.001), and radiotherapy (HR: 0.41; 95% CI: 0.18–0.89; P = 0.025) were independent risk factors of OS in patients with MGCTB. Notably, tumor site (HR: 1.98; 95% CI: 0.99–4.00; P = 0.055) exhibited borderline significance. Additionally, we found that patients with tumors measuring >70 mm (P = 0.015), located in the axial skeleton (P < 0.001) and presented with distant metastasis (P < 0.001) tended to receive radiotherapy. Moreover, a nomogram model integrating independent predictors was established to estimate the OS of patients with MGCTB. This study provides a population-based assessment of the largest number of patients with MGCTB. We found that older age, larger tumor size, regional or distant metastasis, and lack of radiotherapy was associated with poor OS. Surgical methods were not significantly associated with OS. Furthermore, we built a high-quality nomogram to predict 1-, 3-, and 5-year OS for patients with MGCTB. These findings may assist in the clinical diagnosis and treatment of MGCTB. [ABSTRACT FROM AUTHOR]

• Loureirin A attenuates IL-1β induced ECM degradation in chondrocytes. • Loureirin A regulates the NF-κB pathway via Inhibition AKT phosphorylation in IL-1β stimulated chondrocytes. • Loureirin A attenuates IL-1β induced Oxidative stress via activation of Nrf2/HO-1 signaling pathway. • Loureirin A ameliorates the osteoarthritis in vivo. Osteoarthritis(OA) is one of the most common diseases in orthopedics. It is characterized by degeneration of articular cartilage and chronic inflammation. In this study, we aim to elucidate the mechanism of Loureirin A's therapeutic effect in OA progression. In vitro, Loureirin A pretreatment can significantly inhibit production of NO, PGE2, COX-2, TNF-α, iNOS andIL-6 induced by IL-1β in mouse articular chondrocytes. Moreover, Loureirin A suppressed the expression of matrix metalloproteinase-9(MMP-9), which leads to degradation of the extracellular matrix. The degradation of aggrecan and type II collagen protein in the extracellular matrix (ECM) stimulated by IL-1β was reversed. For signal pathway research, Loureirin A dramatically inhibited the phosphorylation of AKT and subsequent NF-κB entering into the nucleus caused by IL-1β in chondrocytes. Besides, a number of related indicators suggested that Loureirin A has a strong antioxidant activity in the treatment of osteoarthritis via increasing content of SOD2 and suppressing MDA and ROS. In addition, in vivo study demonstrated that Loureirin A could ameliorated the progression of OA in mice DMM model In conclusion, all results showed that Loureirin A may be a potential therapeutic candidate for the OA. [ABSTRACT FROM AUTHOR]

Carbon nanofibers were synthesized at 450–800 °C by the catalytic CVD method using alumina plate-supported nickel as catalyst and acetylene as carbon source. It was found that Ni/alumina catalyst exhibited a large catalytic effect on the growth of carbon nanofibers at the temperatures between 550 and 700 °C. TEM observation revealed that most of the carbon nanofibers synthesized at 550 °C had a coil-like shape, and many thick platelet nanofibers were found in the product at 700 °C. A growth model was proposed to explain the structural diversity of the carbon nanofibers. Although the carbon nanofibers showed low crystallinity, they can be easily graphitized at 2500 °C. [Copyright &y& Elsevier]